Evidence map›Paper›PMID 35729402›Full record

ArticleMolecular biomedicine2022

Transglutaminase-2 mediates acquisition of neratinib resistance in metastatic breast cancer.

Aparna Shinde, Eylem Kulkoyluoglu Cotul, Hao Chen, Andrew Smith, Sarah Libring, Luis Solorio, Michael K Wendt

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular biomedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. The Role of Transglutaminase 2 in Cancer: An Update.International journal of molecular sciences · 2024
    Review
  5. Transglutaminase 2 in breast cancer metastasis and drug resistance.Frontiers in cell and developmental biology · 2024
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Aparna ShindeDepartment of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, 47907, USA.
Eylem Kulkoyluoglu CotulDepartment of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, 47907, USA.
Hao ChenDepartment of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, 47907, USA.
Andrew SmithDepartment of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, 47907, USA.
Sarah LibringDepartment of Biomedical Engineering, Purdue University, West Lafayette, IN, 47907, USA.
Luis SolorioDepartment of Biomedical Engineering, Purdue University, West Lafayette, IN, 47907, USA.
Michael K WendtDepartment of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, 47907, USA. mwendt@purdue.edu.
Purdue University West Lafayette · USCenter for Cancer Research · US

Funding

Obesity, Metabolism and Breast Cancer MetastasisR01CA232589 · NCI · PURDUE UNIVERSITY · PI HURSTING, STEPHEN D, TEEGARDEN, DOROTHY · 2019 to 2023
$2.6M
Overcoming metastatic resistance to ErbB-targeted therapiesR01CA207751 · NCI · PURDUE UNIVERSITY · PI WENDT, MICHAEL KEITH · 2017 to 2021
$1.7M
Engineering the Cancer MicroenvironmentR00CA198929 · NCI · PURDUE UNIVERSITY · PI SOLORIO, LUIS · 2017 to 2019
$697k
The influence of alcohol on the metastatic dormancy of breast cancerR21AA026675 · NIAAA · PURDUE UNIVERSITY · PI VAN RIJN, RICHARD M., WENDT, MICHAEL KEITH · 2018 to 2019
$280k
Matrix Accumulation in the Metastatic NicheF99CA264734 · NCI · PURDUE UNIVERSITY · PI LIBRING, SARAH · 2021 to 2022
$94k
NCI NIH HHS F99 CA264734NCI NIH HHS R00 CA198929NCI NIH HHS R00CA198929NCI NIH HHS R01 CA207751NCI NIH HHS R01CA207751NCI NIH HHS R01CA232589NIAAA NIH HHS R21 AA026675NIAAA NIH HHS R21AA026675
6 · The paper itself

Abstract

Acquisition of resistance to targeted therapies remains a major clinical obstacle for the HER2

Indexed as

Breast cancerDrug resistanceHER2IL-6Metastasis

Identifiers

PMID35729402
PMCPMC9213622
OpenAlexW4283271223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.